Hepatitis B Virus (HBV)

CAS No.	Product Name	Inquiry
2634739-74-3	AB-729 AB-729 is a nucleoside analogue that acts as an RNA interference (RNAi) and can inhibit viral replication, reducing HBV antigens. AB-729 binds to a trimer of N-acetylgalactosamine (GalNAc) ligand that promotes entry into hepatocytes through asialoglycoprotein receptor (ASGR).
2645440-65-7	Tobevibart
2648009-64-5	Elebsiran Elebsiran, an antiviral agent against hepatitis B and D virus infections, is a small interfering RNA (siRNA) therapeutic designed to target and silence specific mRNA sequences responsible for the production of pathogenic proteins. Its mechanism of action involves the degradation of targeted mRNA, thereby preventing the synthesis of proteins that contribute to disease progression.
2712529-19-4	HBV-IN-14 HBV-IN-14 is a potent inhibitor of covalently closed circular DNA (cccDNA). cccDNA serves as the template for viral RNA transcription and subsequent viral DNA generation. HBV-IN-14 is a pyridinopyrimidinones compound. HBV-IN-14 has the potential for the research of HBV infection.
2716906-45-3	Hbv-IN-34
2716907-15-0	(5S,8R)-HBV-IN-10 (5S,8R)-HBV-IN-10 is an enantiomer of compound 6 (WO2021204258A1), which is a hepatitis B surface antigen (HBsAg) inhibitor (0.001 μM< EC50 ≤0.05 μM). (Extracted from patent WO2021204258A1, compound 6)
2716907-16-1	HBV-IN-10 HBV-IN-10 is an enantiomer of compound 6 (WO2021204258A1), which is a hepatitis B surface antigen (HBsAg) inhibitor (0.001 μM< EC50 ≤0.05 μM). (Extracted from patent WO2021204258A1, compound 6)
272108-04-0	Oleana-2,12-dien-28-oic acid
2724224-47-7	HBV-IN-6 HBV-IN-6 is a potent inhibitor of HBV with an EC50 of 44 nM. (Extracted from patent WO2021213445A1, compound 3)
2724224-49-9	HBV-IN-7 HBV-IN-7 is a potent inhibitor of HBV with an EC50 of 7 nM. (Extracted from patent WO2021213445A1, compound 5)
2724224-57-9	HBV-IN-8 HBV-IN-8 is a potent inhibitor of HBV with an EC50 of 287.9 nM. (Extracted from patent WO2021213445A1, compound 13)
2724228-72-0	HBV-IN-13 HBV-IN-13 is a potent inhibitor of hepatitis B surface antigen (HBsAg). (Extracted from patent WO2021204252A1, compound 1_B)
2724229-06-3	HBV-IN-12 HBV-IN-12 is a potent inhibitor of hepatitis B surface antigen (HBsAg) (0.001 μM< EC50 ≤0.05 μM). It has anti-HBV DNA activity (0.001 μM
2750254-34-1	HBV-IN-20 HBV-IN-20 is a potent and oral active HBV inhibitor with an EC50 of 0.46 µM. HBV-IN-20 is a typical type II CpAM (core protein assembly modulators).
2826248-50-2	AB-729 sodium
2883679-03-4	HBV/HDV-IN-3
2919019-72-8	ccc_R08
298708-79-9	BAY41-4109 racemic BAY41-4109 racemic, a mixture of R-isomer of BAY41-4109 and S-isomer of BAY41-4109, is an antiviral compound that inhibits HBV replication by destabilizing capsid assembly, with an IC50 of 53 nM.
29984-33-6	ara-Adenosine-5'-monophosphate (ara-AMP) ara-Adenosine-5'-monophosphate (ara-AMP) is an adenosine monophosphate analog with antiviral and possibly antineoplastic properties. It inhibits DNA polymerase and also acts as a chain terminator in DNA replication.
3026061-31-1	Dox-btn2

※ Please kindly note that our services are for research use only.